Nyheter

LIPIGON ENTERS LICENSING AND COLLABORATION AGREEMENT WITH COMBIGENE TO DEVELOP GENE THERAPY FOR LIPO
10 oktober, 2019
“We are very happy to enter this agreement with CombiGene ,” says Stefan K Nilsson, CEO at Lipigon. “Through the development of their epilepsy project, CombiGene has demonstrated a fantastic ability to handle the complexities of gene therapy. With our expertise in lipid biology this collaboration is a perfect match, ultimately aiming at improving the treatment for a patient group with few or no treatment options.” During the upcoming two years, the development of the lipodystrophy project will intensify. The main part of the work will be done at Lipigon and in close collaboration between the two companies.
Fler nyheter
LIPIGON CEO STEFAN K. NILSSON IN INTERVIEW AS INVITED SPEAKER FOR BIOFIT 2016
Nyheter
Lipigon rapporterar säkerhetsdata för högsta doseringsgruppen i Lipisense-studie
Lipigon Pharmaceuticals AB ("Lipigon") presenterade i dag ytterligare positiva säkerhetsresultat frå...
Lipigon presenterar på Stora Aktiedagen den 15 mars
På onsdag den 15 mars deltar Lipigon Pharmaceuticals på Stora Aktiedagen i Stockholm. Bolagets vd St...
Kallelse till extra bolagsstämma i Lipigon Pharmaceuticals AB
Aktieägarna i Lipigon Pharmaceuticals AB, org.nr 556810-9077, ("Bolaget") kallas härmed till extra b...